Andres Bravo-Gonzalez

Dr. Andres Bravo-Gonzalez

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ABAndres Bravo-Gonzalez
Andres Bravo-Gonzalez
MAMaryam Alasfour
Maryam Alasfour
DSDeborah Soong
Deborah Soong
JNJose Noy
Jose Noy
GPGeorgios Pongas
Georgios Pongas
B-cell lymphoid malignancies are a heterogeneous group of hematologic cancers, where Bruton’s tyrosine kinase (BTK) inhibitors have received FDA approval for several subtypes. The first-in-class covalent BTK inhibitor, Ibrutinib, binds to the C481 amino acid residue to block the BTK enzyme and prevent the downstream signaling. Resistance to covalent BTK inhibitors (BTKi) can occur through mutations at the BTK binding site (C481S) but also other BTK sites and the phospholipase C gamma 2 (PLCγ2) resulting in downstream signaling. To bypass the C481S mutation, non-covalent BTKi, such as Pirtobrutinib, were developed and are active against both wild-type and the C481S mutation. In this review, we discuss the molecular and genetic mechanisms which contribute to acquisition of resistance to covalent and non-covalent BTKi. In addition, we discuss the new emerging class of BTK degraders, which utilize the evolution of proteolysis-targeting chimeras (PROTACs) to degrade the BTK protein and constitute an important avenue of overcoming resistance. The moving landscape of resistance to BTKi and the development of new therapeutic strategies highlight the ongoing advances being made towards the pursuit of a cure for B-cell lymphoid malignancies.

17 December 2024 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
ABAndres Bravo-Gonzalez
Andres Bravo-Gonzalez
PDPablo Dominguez-Ruiz
Pablo Dominguez-Ruiz
MGMaría González
María González
SHSara Hira
Sara Hira
CAClaudia Avilés-Covarrubias
Claudia Avilés-Covarrubias
CSCarol L. Shields
Carol L. Shields

21 January 2021 in Ocular Oncology and Pathology
Verified
Journal Article
Closed access
PDF file
MGMaría Elena González
María Elena González
MGMartha Lia Gaviria
Martha Lia Gaviria
MLMariana López
Mariana López
PEPablo Andrés Escudero
Pablo Andrés Escudero
ABAndres Bravo-Gonzalez
Andres Bravo-Gonzalez
SVSergio Alberto Vargas
Sergio Alberto Vargas
Introduction: Intra-arterial chemotherapy (IAC) is useful for eye preservation in advanced retinoblastoma (Rb). Intra-vitreal chemotherapy (IvitC) is the latest treatment for vitreous seeds. Methods: The present study is a retrospective assessment of 100 eyes, treated with primary or secondary IAC alone or with IvitC. We evaluated demographic and clinical variables, eye salvage, associated adverse events, and patient survival. Data were analyzed using descriptive statistics. Kaplan-Meier survival curves and Cox hazard ratios were utilized to assess the effect of demographic and clinical variables over eye salvage. Results: Bilateral Rb was observed in 61% of patients, and 57% of eyes received secondary treatment. Forty eyes needed intra-arterial plus IvitC and 62 presented advanced disease (group D and E). Three- and 5-year ocular survival probabilities were 75 and 68%. We found a higher risk in group D and E eyes and those requiring 2 or more routes for ophthalmic artery catheterization. Patients coming from other countries also showed increased risk. Using primary or secondary treatment, or IvitC, did not affect this risk. Overall rates of survival and eye salvages were 98.8 and 73%, and we had a 100% catheterization success and none ophthalmic arterial occlusions. Conclusions: In an upper middle-income country such as Colombia, a specialized institution counting with therapeutic alternatives and a multidisciplinary team can reach rates of patient survival and eye salvage similar to those of high-income countries.

1 April 2022 in IATREIA
Verified
Journal Article
Open access
PDF file
JBJuan David Bravo
Juan David Bravo
ACAlexandra Correa
Alexandra Correa
ABAndres Bravo-Gonzalez
Andres Bravo-Gonzalez
RBRicardo Bravo
Ricardo Bravo
OVOscar Alonso Villada
Oscar Alonso Villada
Introduction: Diabetes Mellitus (DM) is a worldwide epidemic disease, with significant microvascular compromise. Proliferative diabetic retinopathy (PDR) as well as diabetic macular edema (DME) are currently two of the leading causes of visual impairment and blindness in adults of productive age. Approximately one in three people with DM have diabetic retinopathy (DR), and 1 in 10 have PDR or DME. This study emphasizes in the last one, being the first one with these characteristics in Colombia. Methods: This descriptive cross-sectional study includes 1203 patients diagnosed with DM evaluated in the No more blindness due to diabetes” diabetic retinopathyscreening program of the San Vicente Foundation Hospital in Medellín between 2017 and 2018. The presence of DR and clinical macular edema with the epidemiologic variables were evaluated in a bivariate analysis. Results: From the total number of patients with DM screened (1203), 5,4% (65) had DME, 7,7% had DM type 1 and 89,2% had DM type 2, 10,8% had PDR and 73.8% had nonproliferative diabetic retinopathy NPDR. Most of the patients (93,8%) were diagnosed de novo with DR. The median illness time was 14 years with interquartile range (IQR) between 7 and 19,5. The median glycosylated hemoglobin (HbA1C) was 8.3% (IQR:7,1-11). Optical coherence tomography (OCT) study was done in 28 out of 65 patients with DME (56 out of 130 eyes with DME), in which 85.7% of patients were confirmed to have DME and the mean central macular thickness was 249 microns (IQR:231-341) (n=48 eyes). Conclusion: DM complications were more frequent in patients suffering from DR. The median onset time of DME symptoms was found to be similar to the time of microvascular complications appear; however, it should be considered along with the patient’s metabolic control. Introducción: la diabetes mellitus (DM) es una epidemia mundial. La retinopatía diabética proliferativa (RDP), el edema macular diabético (EMD) y las complicaciones de la diabetes mellitus son las principales causas de discapacidad visual y ceguera en los adultos en la edad productiva. Aproximadamente, 1 de cada 3 personas con DM tiene retinopatía diabética (RD) y 1 de cada 10 tiene RDP o EMD. En el presente estudio se hace énfasis en esta última, siendo el primero con estas características en Colombia. Métodos: estudio transversal descriptivo donde se incluyeron 1.203 pacientes con diagnóstico de DM atendidos en la jornada “No más ciegos por Diabetes” del Hospital San Vicente Fundación de Medellín, en el 2017 y 2018. Se evaluó la presencia de RD y EMD clínico y sus características pidemiológicas en un análisis bivariado. Resultados: del total de pacientes con DM tamizados (1.203), el 5,4 % (65) tenían EMD; dentro de estos, el 7,7 % tenía DM tipo 1 y el 89,2 % DM tipo 2. El 10,8 % tenía RDP, 73,8 % tenía RD no proliferativo (RDNP). En un 93,8 % se hizo diagnóstico de novo de RD. La mediana del tiempo de la diabetes fue de 14 años, con un rango intercuartílico (RIQ) entre 7 y 19,5. La mediana de la hemoglobina glicosilada (HbA1C) fue de 8,3 % (RIQ: 7,1-11). De 65 pacientes con EMD, 28 (56 ojos de los 130 con EMD) fueron estudiados con tomografía de coherencia óptica (OCT) y al 85,7 % se le confirmó EMD. La mediana del grosor macular central fue de 249 micras (RIQ: 231-341) en los pacientes con EMD por OCT (n = 48 ojos). Conclusión: las complicaciones de la diabetes son más prevalentes en los pacientes con RD. La media del tiempo de aparición de EMD fue similar al tiempo de inicio de las complicaciones microvasculares de la diabetes reportada en la literatura, pero debe ser considerada en el contexto del control metabólico de los pacientes.

10 December 2023 in Infectio
Verified
Journal Article
Open access
PDF file
ABAndres Bravo-Gonzalez
Andres Bravo-Gonzalez
DVDaniel Villa-Tamayo
Daniel Villa-Tamayo
TGTomás Giraldo-Hinestroza
Tomás Giraldo-Hinestroza
NMNicolás Manjarrés-Sierra
Nicolás Manjarrés-Sierra
DCDiego Córdoba-Alzate
Diego Córdoba-Alzate
NCNora Cardona-Castro
Nora Cardona-Castro
Objetivo: Identificar el perfil de parasitosis intestinales en menores de 18 años y las características modificables y no modificables asociadas de cuatro poblaciones en los municipios de Quibdó, Apartadó, Guachené y Granada, Colombia, en 2012. Material y método: Se realizó un estudio transversal donde se evaluó una fuente secundaria de información obtenida de cuatro municipios de Colombia (Guachené, Quibdó, Apartadó y Granada) sobre la cual se analizaron de manera univariada y bivariada los factores sociodemográficos asociados a la presencia de parásitos. Resultado: Se analisaron 240 individuos. dos tercios (66.67%) de ellos se encontraron parasitados. Las especies más frecuentes fueron Entamoeba histolytica/dispar (22.9%), Endolimax nana (19.2%), Blastocystis hominis (19.2%), Giardia intestinalis (20.8%). Se observó una asociación entre la disposición inadecuada de excretas (letrina o pozo séptico) y la presencia de colonización parasitaria en comparación al uso de sanitario con una razón de prevalencia (PR) de 1.34 [1.14, 1.59] (p=0.005). Similarmente, la construcción de vivienda con madera o bahareque demostró ser un factor 1.31 veces más frecuente en sujetos con presencia de formas parasitarias en el coprológico que aquellos con casas de ladrillo. Discusión: Se encontró una mayor frecuencia de parásitos intestinales para los diferentes grupos etáreos comparado con varios de los reportes a nivel mundial y en latinoamérica. Sin embargo, no hubo diferencias significativas entre los grupos de edad a diferencia de otros estudios. Las especies más frecuentes de parásitos fue similar a lo reportado en la literatura. Factores asociados a un mayor riesgo de parásitos intestinales como la disposición de excretas ya se han descrito en otros estudios. Conclusiones: Poblaciones aisladas de Colombia como las estudiadas presentan mayor frecuencia de parásitos intestinales que otras poblaciones comparadas y los factores de vivienda y acceso a servicios públicos permanecen como factores que aumentan el riesgo de parásitos intestinales.

3 August 2023 in Revista Colombiana de Hematología y Oncología
Verified
Journal Article
Open access
PDF file
MLMauricio Lema
Mauricio Lema
NQNéstor Eduardo Llinás Quintero
Néstor Eduardo Llinás Quintero
ABAndres Bravo-Gonzalez
Andres Bravo-Gonzalez
JHJuan Camilo Hernández
Juan Camilo Hernández
During the COVID-19 pandemic, regulatory approval or expanded indications were granted for several immune checkpoint inhibitors in cancer treatment in Colombia. However, for various reasons, the practicing medical community faced difficulties in accessing updated information on these new indications. Objective: to review the new approvals by the National Institute for Food and Drug Surveillance (INVIMA) for immune checkpoint inhibitors with approvals issued between March 2020 and May 2022. Methods: New indications for immune checkpoint inhibitors were searched on the INVIMA website and in media sources. For cost information, Circular 12 for regulated drugs or the reference prices from the Drug Price Information System (SISMED) for unregulated drugs were consulted. A brief literature review was conducted for each indication, with a focus on study design, primary outcomes, grade 3 or higher toxicities, and estimated costs in Colombia. Results: New therapeutic indications were found for ipilimumab (anti-CTLA4), nivolumab (anti-PD1), pembrolizumab (anti-PD1), atezolizumab (anti-PD-L1), durvalumab (anti-PD-L1), and avelumab (anti-PD-L1). Nine new indications were approved between March 2020 and May 2022. Pembrolizumab obtained four new indications, including for colorectal cancer with microsatellite instability or DNA mismatch repair deficiency, triple-negative breast cancer, esophageal cancer, and Hodgkin's lymphoma. The combination of atezolizumab and bevacizumab is indicated for advanced hepatocellular carcinoma. Ipilimumab plus nivolumab (with chemotherapy) is approved for metastatic non-small cell lung cancer. Durvalumab in combination with chemotherapy is indicated for extensive-stage small cell lung cancer. Avelumab is approved for maintenance therapy in advanced urothelial cancer and in combination with axitinib for metastatic renal cell carcinoma. The toxicities observed in the registration studies are consistent with the expected profile for this class of agents. Conclusion: The expansion of the number and scope of regulatory approvals for immune checkpoint inhibitors in Colombia presents an additional opportunity for the benefit of cancer patients.